With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

As the global demand for obesity treatments skyrockets, Vikrant Shrotriya discusses the complex nature of obesity, the ...

Research suggests potential health benefits beyond what popular diabetes and weight-loss drugs were first approved to treat.

While Novo Nordisk ... disease for some 45 years, the field has often taken a back seat to the Danish drugmaker’s bread-and-butter business developing treatments for diabetes and other common ...

head of development at Novo Nordisk, noted that hypertension is a leading risk factor for cardiovascular events, heart failure, chronic kidney disease, and premature death. “With its expected ...

Novo Nordisk has gone ... like heart failure and kidney disease – as it tries to stay ahead of rivals like Eli Lilly. Demand for its semaglutide-based therapies Ozempic for diabetes and Wegovy ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.